【摘要】：Polo樣激酶(polo-like kinase, Plk)是一類廣泛存在于真核生物中的絲氨酸/蘇氨酸蛋白激酶。其中,Plkl調(diào)控細胞有絲分裂多個環(huán)節(jié),在80%人類腫瘤細胞中過度表達,包括乳腺癌、結(jié)腸直腸癌、前列腺癌、胰腺癌、非小細胞肺癌、卵巢癌等,但在正常組織中很少表達。抑制Plkl的活性可以產(chǎn)生良好的抗癌效果,因而Plkl是一個很好的抗腫瘤藥物研發(fā)的靶點。目前,已有眾多Plkl小分子靶向抑制劑被報道,但仍存在著Plk家族內(nèi)部選擇性差、藥代動力學方面的諸多問題,開發(fā)特異性、可口服的Plkl抑制劑因此至關(guān)重要。本研究采用基于結(jié)構(gòu)的藥物設(shè)計理論,以首個進入臨床實驗的Plkl抑制劑BI2536為先導化合物,保留其核心藥效團骨架,利用家族內(nèi)部氨基酸殘基的細微差異,進行特異性的結(jié)構(gòu)修飾從而達到提高活性與選擇性的目的,再利用計算機輔助軟件進行虛擬評價,設(shè)計并合成了27個結(jié)構(gòu)新穎的全新化合物。最后,采用體外激酶抑制實驗與抗腫瘤細胞株實驗對化合物進行生物學評價。測試結(jié)果表明,所設(shè)計的大部分化合物均對Plkl產(chǎn)生了低納摩爾濃度的抑制活性以及家族內(nèi)部的選擇性。其中化合物C2對Plkl的ICso值達到了4.134 nM,優(yōu)于陽性對照物BI2536和十字孢堿,并且將家族內(nèi)部Plk2、Plk3的選擇性分別提高至54倍和35倍。同時該化合物對體外MCF-7、K562、Hela癌細胞株的抑制活性分別為40.69 nM、41.67 nM、37.71 nM,同樣優(yōu)于陽性對照物BI 2536與紫杉醇。本課題初步篩選出了一系列高效、低毒、結(jié)構(gòu)新穎的Plkl抑制劑,為進一步開發(fā)新型高效的抗癌藥物奠定了基礎(chǔ)。
文內(nèi)圖片：
圖片說明：圖１．２邐（ａ）抑制劑與ＮＣＤ邋口袋的結(jié)合模式；（ｂ）抑制劑與ＰＢＤ邋口袋的結(jié)合模式逡逑Ｆｉｕｒｅ邋１．２ａＴｈｅ邋ｂｉｎｄｉｎｍｏｄｅ邋ｏｆ邋ｉｎｈ化ｉｏｒ邋ｗｉｈ邋化ｅ邋ＮＣＤｂＴｈｅ邋ｂｉｎｄｉｎｍｏｄｅ邋ｏｆ邋ｉｎｈ化ｉｔｏｒ邋ｗｉｔｈ逡逑
[Abstract]:Polo-like kinase (polo-like kinase, Plk) is a kind of serine / threonine protein kinase which widely exists in eukaryotes. Among them, Plkl regulates mitosis and is overexpressed in 80% of human tumor cells, including breast cancer, colorectal cancer, prostate cancer, pancreatic cancer, non-small cell lung cancer, ovarian cancer and so on, but rarely expressed in normal tissues. Inhibition of Plkl activity can produce good anticancer effect, so Plkl is a good target for antitumor drug development. At present, many Plkl small molecule targeting inhibitors have been reported, but there are still many problems in Plk family, such as poor selectivity and pharmacokinetics. It is very important to develop specific and oral Plkl inhibitors. In this study, the structure-based drug design theory was used, the first Plkl inhibitor BI2536, which entered the clinical trial, was used as the lead compound to retain its core pharmacophore skeleton, and the specific structure modification was carried out by using the nuances of amino acid residues within the family to improve the activity and selectivity. 27 new compounds with novel structure were designed and synthesized by virtual evaluation with computer-aided software. Finally, the biological evaluation of the compounds was carried out by in vitro kinase inhibition test and anti-tumor cell line test. The results showed that most of the compounds produced low nanomolconcentration inhibitory activity and intra-family selectivity to Plkl. The ICSO value of compound C2 to Plkl was 4.134 nM, which was better than that of BI2536 and Cruciferine, and the selectivity of Plk2,Plk3 in the family was 54 times and 35 times, respectively. At the same time, the inhibitory activity of the compound on MCF-7,K562,Hela cell line in vitro was 40.69 nM,41.67 nM,37.71 nM, which was also better than that of BI 2536 and paclitaxel, respectively. In this paper, a series of Plkl inhibitors with high efficiency, low toxicity and novel structure were screened out, which laid a foundation for the further development of new and efficient anticancer drugs.
【學位授予單位】：合肥工業(yè)大學
【學位級別】：碩士
【學位授予年份】：2016
【分類號】：R914;R96

【相似文獻】

相關(guān)期刊論文 前7條

1 徐洪;一氧化氮合酶選擇性抑制劑設(shè)計的生化基礎(chǔ)[J];國外醫(yī)學.藥學分冊;1998年04期

2 徐云根,羅穗,華維一;誘生型一氧化氮合酶選擇性抑制劑的研究[J];藥學進展;2000年03期

3 張述耀;方翎;朱志偉;趙樹林;;非甾體類環(huán)氧化酶-2選擇性抑制劑與抗腫瘤作用機制探討[J];中國醫(yī)院藥學雜志;2010年22期

4 吳卓娜;竇梅芝;孟志云;;COX-2選擇性抑制劑及其心血管安全性研究進展[J];解放軍藥學學報;2009年01期

5 溫新民;非甾體類抗炎藥—環(huán)氧化酶-2選擇性抑制劑研究新進展[J];濟寧醫(yī)學院學報;2004年04期

6 羅劍剛;李慧;楊聰嫻;;COX-2選擇性抑制劑治療疼痛的研究進展[J];中國疼痛醫(yī)學雜志;2012年02期

7 ;[J];;年期

相關(guān)重要報紙文章 前1條

1 記者 白毅;篩選出具有抑腫瘤活性的Plk1高選擇性抑制劑[N];中國醫(yī)藥報;2009年

相關(guān)碩士學位論文 前4條

1 王雪萌;含硝基的贗二肽類化合物作為基質(zhì)金屬蛋白酶-7選擇性抑制劑的研究[D];延邊大學;2016年

2 楊洋;基于結(jié)構(gòu)的Plk1選擇性抑制劑的設(shè)計、合成及抗腫瘤活性研究[D];合肥工業(yè)大學;2016年

3 于海俠;抗耐藥作用的Bcr-Abl選擇性抑制劑的設(shè)計、合成與篩選[D];廣西大學;2006年

4 汪鳳穎;新型COX-2選擇性抑制劑的分子設(shè)計研究[D];北京化工大學;2005年

，

本文編號：2510242